Zydus gets USFDA nod for antiviral drug used in HIV treatment
Zydus Lifesciences obtained final clearance from the USFDA for Darunavir Tablets, an antiviral medication used in treating HIV-1 infection. Darunavir, a protease inhibitor, restricts HIV-1 multiplication and is prescribed for adults and pediatric patients over three years old. Co-administration with Ritonavir and other antiretroviral agents is necessary. Manufactured in Ahmedabad, Gujarat, the medication holds significant market potential, recording USD 275 million in annual US sales. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 15, 2023 Category: Pharmaceuticals Source Type: news

Aurobindo Pharma gets USFDA nod for HIV drug
Darunavir tablets, 600 mg and 800 mg, in combination with other antiretroviral agents, are indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 29, 2023 Category: Pharmaceuticals Source Type: news

Lupin gets USFDA nod for generic HIV drug
Drug firm Lupin on Tuesday said it has received an approval from the US health regulator to market Darunavir Tablets, used to treat Human Immunodeficiency Virus (HIV) infection, in the American market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 4, 2022 Category: Pharmaceuticals Source Type: news

Dual Therapy Holds Its Own in Treatment-Naive HIV
(MedPage Today) -- MONTREAL -- A two-drug combination using a generic formulation of the protease inhibitor darunavir/ritonavir plus lamivudine appeared to control HIV as well as the same combination with added tenofovir, according to results... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - August 2, 2022 Category: Infectious Diseases Source Type: news

' Important' New Data on Second-Line HIV Treatment Regimens: The NADIA Study'Important' New Data on Second-Line HIV Treatment Regimens: The NADIA Study
For second-line HIV therapy, both dolutegravir and ritonavir-boosted darunavir regimens, plus two nucleoside reverse-transcriptase inhibitors (NRTIs), maintained good viral suppression during 96 weeks follow-up in the NADIA trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2022 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Prezcobix (darunavir and cobicistat)
Title: Prezcobix (darunavir and cobicistat)Category: MedicationsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 30, 2021 Category: Infectious Diseases Source Type: news

Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide)
Title: Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide)Category: MedicationsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 30, 2021 Category: Infectious Diseases Source Type: news

Prezista (darunavir)
Title: Prezista (darunavir)Category: MedicationsCreated: 2/22/2021 12:00:00 AMLast Editorial Review: 2/22/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 22, 2021 Category: Drugs & Pharmacology Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news